Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1994-06-10
1998-07-21
Fonda, Kathleen K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 54, 514 56, 514 57, 514 61, 514 2, 514 8, 514 62, 536 21, 536 56, 5361231, 53612313, A61K 31715, C08B 3710
Patent
active
057835683
ABSTRACT:
The present invention relates to a method of treating in a mammal certain cancers, other cell proliferative diseases, and/or angiogenesis by using a salt or complex of a sulfated saccharide. The invention also relates to the use of mutant heparin binding growth factors that bind to the growth factor receptor, but not to heparin. The invention also provides pharmaceutical compositions for such methods.
REFERENCES:
patent: 4021544 (1977-05-01), Nair et al.
patent: 5039529 (1991-08-01), Bergendahl et al.
patent: 5143829 (1992-09-01), Thompson et al.
patent: 5164378 (1992-11-01), Conti et al.
patent: 5202311 (1993-04-01), Folkman et al.
patent: 5223483 (1993-06-01), Thomas et al.
patent: 5362641 (1994-11-01), Fuks et al.
patent: 5401721 (1995-03-01), Folkman et al.
patent: 5401832 (1995-03-01), Linemeyer et al.
Gitay-Goren et al., 1992, "The Binding of Vascular Endothelial Growth Factor to Its Receptors Is Dependent on Cell Surface-associated Heparin-like Molecules", J. Biol. Chem. 267:6093-6098.
Hattori et al., 1990 "Suramin Interrupts Androgen-Inducible Autocrine Loop Involving Heparin Binding Growth Factor in Mouse Mammary Cancer (Shionogi Carcinoma 115) Cells ", Proc. Natl. Acad. Sci. 87:5983-5987.
Kan et al., 1993, "An Essential Heparin-Binding Domain in the Fibroblast Growth Factor Receptor Kinase," Science 259: 1918-1921.
Kasayama et al., 1993, "Suramin Interrupts Androgen-Inducible Autocrine Loop Involving Heparin Binding Growth Factor in Mouse Mammary Cancer (Shionogi Carcinoma 115) Cells, " J. Cell. Phy. 154:254-261.
Klagsbrun et al., 1991, "A Dual Receptor System Is Required For Basic Fibroblast Growth Factor Activity," Cell 67:229-231.
Konturek et al., 1989, "Epidermal Growth Factor in the Gastroprotective and Ulcer-Healing Actions of Sucralfate in Rats," Am. J. Med. 86:32-37.
Konturek et al., 1993, "Fibroblast growth factor in gastroprotection and ulcer healing: interaction with sucralfate," Gut 34:881-887.
La Rocca et al., 1990, "Suramin: Prototype of a New Generation of Antitumor Compounds," Cancer Cells 2:106-115.
Mach et al., 1993, "Nature of the Interaction of Heparin with Acidic Fibroblast Growth Factor," Biochemistry 32:5480-5489.
Schlessinger et al., 1992, "Growth Factor Signaling by Receptor Tyrosine Kinases," Neuron 9:383-391.
Ullrich et al., 1990, "Signal Transduction by Receptors with Tyrosine Kinase Activity," Cell 6:203-212.
Wagner, 1991, "The Fibroblast Growth Factors: An Emerging Family of Neural Growth Factors," Curr. Top. Microbiol. Immunol. 165:95-118.
Wellstein et al., 1991, "Tumor Growth Dependent on Kaposi's Sarcoma-Derived Fibroblast Growth Factor Inhibited by Pentasan Polysulfate," J. Natl. Cancer Inst. 83:716-720.
Yamaguchi et al., 1994, "Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas," Proc. Natl. Acad. Sci. 91:484-488.
Yayon et al., "Cell Surface, Heparin-like Molecules Are Required for Binding of Basic Fibroblast Growth Factor to Its High Affinity Receptor," Cell 64:841-848.
Zhu et al., "1993 Structural studies of the binding of the anti-ulcer drug sucrose octasulfate to acidic fibroblast growth factor," Structure 1:27-34.
Fugedi et al. XVIth International Carbohydrate Symposium, Jul. 5-10, 1992, Paris, France, Abstract No. B113, p. 446.
Fugedi et al. XVIth International Carbohydrate Symposium, Jul. 5-10, 1992, Paris, France, Abstract No. B069, p. 402.
Ladbury John E.
Lax Irit
Schlessinger Joseph
Tang Peng Cho
Fonda Kathleen K.
New York University
Sugen Inc.
LandOfFree
Methods for treating cancer and other cell proliferative disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating cancer and other cell proliferative disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating cancer and other cell proliferative disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1647252